Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure-Reference-Cited by-同舟云学术

Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure

Published:2016-11-09 Issue:4 Volume:57 Page:440-451
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Voors Adriaan Alexander¹,Düngen Hans-Dirk²,Senni Michele³,Nodari Savina⁴,Agostoni Piergiuseppe⁵,Ponikowski Piotr⁶,Bax Jeroen J.⁷,Butler Javed⁸,Kim Raymond J.⁹,Dorhout Bernard¹,Dinh Wilfried¹⁰,Gheorghiade Mihai¹¹

Affiliation:

1. Department of Cardiology; University Medical Center Groningen; University of Groningen; Groningen the Netherlands

2. Department of Cardiology; Campus Virchow, Charite Universitätsmedizin Berlin; Berlin Germany

3. Cardiovascular Department; Ospedale Papa Giovanni XXIII; Bergamo Italy

4. Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health; University and Civil Hospital of Brescia; Brescia Italy

5. Centro Cardiologico Monzino; Milan Italy

6. Wroclaw Medical University; Wroclaw Poland

7. Department of Cardiology; Leiden University Medical Center; Leiden the Netherlands

8. Division of Cardiology; Stony Brook University; Stony Brook NY, USA

9. Duke Cardiovascular Magnetic Resonance Center; Duke University Medical Center; Durham NC, USA

10. Department of Cardiology, Witten, Germany; Drug Discovery, Clinical Sciences, Bayer Pharma AG; Witten University; Wuppertal Germany

11. Center for Cardiovascular Innovation; Northwestern University Feinberg School of Medicine; Chicago IL, USA

Funder

Bayer Pharma AG

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference24 articles.

1. Partial adenosine A1 receptor agonists for cardiovascular therapies;Albrecht-Kupper;Purinergic Signal,2012

2. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure;Greene;Heart Fail Rev,2016

3. Adenosine A1 receptor activation attenuates cardiac hypertrophy and fibrosis in response to alpha1 -adrenoceptor stimulation in vivo;Puhl;Br J Pharmacol,2016

4. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials;Bulluck;Int J Cardiol,2016

5. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors;Fredholm;Pharmacol Rev.,2001

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets;Frontiers in Cardiovascular Medicine;2023-06-02

2. Problems and prospects for finding new pharmacological agents among adenosine receptor agonists, antagonists, or their allosteric modulators for the treatment of cardiovascular diseases;Biomeditsinskaya Khimiya;2023

3. Once Upon a Time Adenosine and Its Receptors: Historical Survey and Perspectives as Potential Targets for Therapy in Human Diseases;Topics in Medicinal Chemistry;2023

4. Experimental heart failure models in small animals;Heart Failure Reviews;2022-12-12

5. The Role of Purinergic Signaling in Heart Transplantation;Frontiers in Immunology;2022-04-21